193.46 USD
▲-4.64+6.03%
盘后 187.53 0.00%
2026-07-31
市值
$41.13B
市盈率
—
EPS
-7.12
股息率
—
52 周区间
34.00 – 194.56
成交量
1.61M
Beta
1.38
目标价
207.00
52W 低 34.0052W 高 194.56
价格走势
公司简介
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236)...